The Analgesic Effect: How the Body Biologically Stops Pain

Your body runs a sophisticated pain-suppression network that operates at every level of the nervous system, from the skin where a signal first fires all the way up to the prefrontal cortex where you decide how much that signal matters. This network uses its own opioids, its own cannabis-like molecules, dedicated brain circuits that can dial pain up or down, and even immune cells that rush to an injury site and release painkillers locally. Understanding how the body stops pain is not just an academic exercise; it explains why a soldier can be shot and not feel it until later, why exercise reduces soreness, why placebos genuinely work, and why chronic pain represents a failure of systems that normally keep discomfort in check.

The Spinal Gate

The first checkpoint for pain signals sits in the spinal cord, in a region called the substantia gelatinosa. The concept, broadly known as the gate theory, proposes that large-diameter nerve fibers carrying touch and pressure information can reduce the transmission of pain signals carried by smaller fibers. When you rub a bumped elbow, the touch signals from large fibers activate inhibitory circuits that dampen the pain signals trying to pass through to the brain. In the original framework, these inhibitory circuits act like a gate: touch-related input closes it, while sustained pain input from small fibers opens it.¹

The nerve fibers involved fall into distinct categories. A-delta fibers are thinly insulated and carry sharp, fast pain, while C fibers are uninsulated and carry the dull, burning pain that lingers. Both types project into the spinal cord, where their signals can be modulated before ever reaching the brain.² At that spinal level, inhibitory neurons that use GABA and glycine act as brakes. Research in animal models shows that C fiber signals are dampened mainly through glycine-based inhibition, while A-delta input is suppressed through a mix of GABA and glycine working together.³ These local inhibitory circuits are the first biological barrier between a painful stimulus and the conscious experience of pain.

The Body’s Own Opioids

Your nervous system manufactures molecules that function almost identically to morphine. The best known is beta-endorphin, which is produced by clipping a larger precursor protein called POMC. Beta-endorphin acts primarily on mu opioid receptors distributed throughout the brain, spinal cord, and immune system, producing powerful pain relief along with effects on mood and reward.⁴ But beta-endorphin is only one member of the family. Enkephalins prefer delta opioid receptors, and dynorphins prefer kappa opioid receptors. Each type dampens pain through slightly different pathways, and all three are produced not just in the brain but also by immune cells at sites of injury.

This system is activated by many triggers: acute stress, vigorous exercise, laughter, social bonding, even anticipation of relief. When pharmaceutical opioids like morphine or fentanyl enter the picture, they are hijacking receptors that evolved to respond to these endogenous molecules. The potency of the body’s own supply is limited compared with concentrated drugs, but it is remarkably targeted and self-regulating under normal circumstances.

Descending Pain Control From the Brain

The brain does not passively receive pain signals; it actively sends instructions back down the spinal cord to turn the volume up or down. The best-characterized pathway runs from the periaqueductal gray, a region deep in the midbrain, to the rostral ventromedial medulla in the brainstem, and from there to the spinal cord. This PAG-RVM circuit is often called the descending pain modulation system, and it is the primary route by which the brain suppresses pain at the spinal level.⁵

The PAG-RVM pathway uses mu opioid receptors as a key switch. When those receptors are blocked, the descending inhibition largely shuts off. Activating PAG neurons reduces pain sensitivity, while inhibiting them makes pain worse, a relationship that has been demonstrated in chronic stress models where the circuit’s dysfunction contributes to lasting pain.⁶ The descending system also connects to the brain’s reward and motivation circuits. A painful stimulus can trigger an ascending signal to the mesolimbic system, which then activates the PAG-RVM pathway to suppress the very pain that triggered it, creating a feedback loop.⁵

Serotonin and Norepinephrine as Pain Brakes

The descending system does not rely on opioids alone. Two neurotransmitters that most people associate with mood, serotonin and norepinephrine, are also major players in pain suppression. Nerve fibers carrying norepinephrine and serotonin project from the brainstem directly into the spinal dorsal horn, where pain signals are being processed.⁷

Animal studies show that norepinephrine is the more consistently pain-suppressing of the two. Serotonin has inhibitory effects on both A-delta and C fiber input to spinal neurons, while norepinephrine selectively inhibits C fiber input to certain types of spinal cells.⁸ Noradrenergic interventions are generally more effective at reducing pain-related behavior in animal models, with serotonergic interventions playing a supporting role.⁹ This is exactly why a class of antidepressants called SNRIs, which boost both serotonin and norepinephrine, are prescribed for chronic pain conditions like fibromyalgia and diabetic neuropathy. They work not because the patient is depressed, but because the same neurotransmitters that regulate mood also regulate pain at the spinal level.

The Endocannabinoid System

Your body also produces its own cannabis-like molecules, called endocannabinoids. The two main ones, anandamide and 2-AG, bind to cannabinoid receptors distributed throughout the nervous system and immune cells. CB1 receptors sit primarily in the brain and spinal cord, where they regulate neurotransmitter release and shape pain perception. CB2 receptors are concentrated on immune cells and peripheral tissues such as dorsal root ganglia, where they reduce inflammation and modulate immune-related pain signaling.¹⁰

The endocannabinoid system interacts with the opioid system in ways researchers are still untangling. During exercise, for example, levels of 2-AG rise regardless of whether opioid receptors are blocked, suggesting the endocannabinoid system can suppress pain independently. But anandamide levels seem to depend partly on opioid system activity, hinting at crosstalk between the two systems.¹¹ This dual system gives the body redundancy: if one pain-suppression pathway is overwhelmed or blocked, the other can still provide some relief.

When Stress Numbs Pain

Nearly everyone has heard a story about someone who suffered a severe injury and felt nothing until the crisis was over. This phenomenon, called stress-induced analgesia, is real and well-documented. It comes in two distinct forms. Intermittent, prolonged stress tends to activate opioid-based pain suppression, while brief, continuous stress activates a separate, non-opioid mechanism.¹² The distinction matters: tolerance develops to the opioid form with repeated exposure, but not to the non-opioid form, and cross-tolerance does not occur between them.¹³

What makes this especially interesting is that these two systems actively inhibit each other. When opioid pathways are blocked pharmacologically, the non-opioid pain suppression actually gets stronger, suggesting the opioid system normally holds the non-opioid system partially in check.¹⁴ This competitive relationship may serve as a safety valve, ensuring that some form of pain suppression remains available regardless of which system is active or depleted.

Exercise-Induced Hypoalgesia

The pain relief that follows vigorous exercise is not just psychological. Intense resistance training elevates plasma beta-endorphin concentrations, and the pain reduction in exercised muscles can persist for up to 24 hours.¹⁵ Research using opioid-blocking drugs has shown that pain relief still occurs even when opioid receptors are blocked, which points to the endocannabinoid system as a parallel contributor. Specifically, 2-AG levels rise after exercise regardless of opioid blockade, while anandamide levels rise only when the opioid system is intact.¹¹

The practical implication is that exercise engages multiple analgesic systems simultaneously. This is one reason physical therapy and regular exercise are recommended for many chronic pain conditions: the body is not just getting stronger or more flexible, it is actively producing its own pain-relief chemistry.

Pain That Inhibits Pain

One of the more counterintuitive findings in pain research is that applying a second painful stimulus can reduce the perception of the first. If you immerse your hand in painfully cold water while receiving a mild heat stimulus on your arm, the heat feels less painful. This phenomenon, called conditioned pain modulation, reflects a brainstem-level circuit where one noxious input activates descending inhibition that suppresses a different noxious input. Brain imaging reveals that the analgesic effect correlates with reduced neural activity in three specific brainstem regions: the spinal trigeminal nucleus, the subnucleus reticularis dorsalis, and the parabrachial nucleus in the dorsolateral pons.¹⁶

Clinicians now test conditioned pain modulation as a way to assess how well a person’s descending inhibitory system is functioning. People with chronic pain conditions often show reduced conditioned pain modulation, meaning their brains are less effective at using this “pain cancels pain” mechanism. This test is becoming a useful predictor of who might develop chronic pain after surgery or injury.

Immune Cells as Local Painkillers

Pain suppression is not confined to the nervous system. When tissue becomes inflamed, immune cells migrate to the site and begin producing opioid peptides locally. Beta-endorphin-containing lymphocytes accumulate at inflamed tissue and release their payload directly onto sensory nerve endings in the area.¹⁷ Signaling molecules like interleukin-1 beta and corticotropin-releasing factor trigger immune cells to release beta-endorphin, which then binds to opioid receptors on nearby sensory nerves and dampens pain right at the source.¹⁸

This local immune-mediated analgesia extends beyond beta-endorphin. Immune cells at inflamed sites also produce and release enkephalins and dynorphins, which act on delta and kappa opioid receptors respectively. Corticotropin-releasing factor stimulates this release in a dose-dependent manner, and the resulting pain relief can be reversed by blocking the specific opioid peptide involved.¹⁹ The body, in other words, deploys a localized opioid pharmacy directly to the site of injury, independent of what the brain is doing.

Placebo and Cognitive Modulation

Placebo analgesia is not imaginary pain relief; it is pain relief produced by real neurobiological machinery. Functional and molecular brain imaging studies have shown that placebo treatments activate the dorsolateral prefrontal cortex and trigger endogenous opioid release in the brain.²⁰ In essence, expecting pain relief causes the brain to produce its own pain relief using the same opioid pathways that respond to real drugs. This is why naloxone, which blocks opioid receptors, can partially reverse placebo analgesia in some studies.

Mindfulness meditation engages related but distinct brain mechanisms. Practiced meditators show increased activity in the anterior cingulate cortex and anterior insula during painful stimulation, brain regions involved in the cognitive regulation of pain processing.²¹ The evidence suggests that mindfulness reduces pain through enhanced cognitive and emotional control, as well as by changing how the brain evaluates sensory events contextually.²² Attention, expectation, mood, and conditioning all feed into the same descending pathways discussed earlier, which means that “it’s all in your head” is technically correct but deeply misleading. The head is where all the pain control hardware lives.

The Vagus Nerve and Autonomic Pain Control

The vagus nerve, the longest cranial nerve in the body, provides another route to pain modulation. Vagus nerve stimulation engages key pain-regulatory structures including the periaqueductal gray, locus coeruleus, and nucleus of the solitary tract.²³ Even non-invasive transcutaneous stimulation of the vagus nerve at the ear can produce analgesic effects through multiple interconnected mechanisms: activating descending pain control, modulating the cholinergic anti-inflammatory pathway, rebalancing autonomic nervous system tone, remodeling brain network connectivity, adjusting neurotransmitter levels, and inhibiting peripheral and central sensitization.²⁴ The vagus nerve essentially provides a physical wire connecting the body’s autonomic regulation system to its pain suppression hardware.

Sex Differences in Pain Inhibition

Men and women do not suppress pain using the same balance of systems. In rat models, blocking opioid receptors almost completely eliminated a specific phase of pain inhibition in females but had only a small effect in males, indicating that females relied heavily on opioid mechanisms while males used a predominantly non-opioid pathway for the same inhibitory process. Gonadectomy experiments confirmed that sex hormones modulate which system predominates.²⁵

Brain connectivity patterns also differ. Males show stronger functional connections between the anterior cingulate cortex and the PAG, hippocampus, and deep mesencephalic nucleus, while females show stronger connectivity between the anterior cingulate cortex and the locus coeruleus, pontine reticular formation, and other brainstem regions.²⁶ These differences matter clinically because pain medications that target one system over another may work differently depending on sex, and they help explain why women are disproportionately affected by certain chronic pain conditions.

When the Clock Matters

Pain sensitivity is not constant throughout the day. Multiple components of the pain system run on circadian rhythms, including the descending modulation pathways, opioid system activity, endocrine fluctuations, and immune function. No single brain region is responsible for the daily oscillation in pain perception; instead, it emerges from the interaction of rhythms distributed throughout the entire pain system.²⁷ For most people, pain tolerance tends to be lowest in the early morning hours and highest in the afternoon, although the pattern varies with individual chronotype and sleep quality. This has real implications for scheduling medical procedures, timing pain medications, and understanding why chronic pain flares often follow disrupted sleep.

The Gut Microbiome’s Role

An emerging body of research connects gut bacteria to pain modulation. Gut microbiota produce signaling molecules, metabolites, neurotransmitters, and neuromodulators that regulate both peripheral and central sensitization. In the central nervous system, microbiome-derived mediators influence neuroinflammation by affecting the blood-brain barrier, microglia activation, and infiltrating immune cells, all of which contribute to the maintenance of central sensitization and chronic pain states.²⁸ The gut microbiome may also contribute to central sensitization of chronic pain through its regulation of microglia and astrocytes, and disruptions in the gut microenvironment have been linked to chronic visceral pain in conditions like irritable bowel syndrome.²⁹

Early Life Experiences and Epigenetic Shaping

The body’s pain suppression systems are not static; they are shaped by experience, particularly early in life. Epigenetic modifications, chemical changes to DNA or its associated proteins that alter gene expression without changing the genetic code, are especially active during prenatal and early postnatal periods. Exposure to trauma during these critical windows, including in-utero stress or adverse childhood experiences, can alter epigenetic regulation in the brain and modify how pain-related processes function for life.³⁰ These modifications may contribute to neural reorganization that underpins central sensitization, the process by which the nervous system amplifies pain signals, potentially explaining why early-life adversity is a risk factor for chronic pain conditions in adulthood.

Genetic Extremes

Rare genetic mutations offer a dramatic illustration of how central pain suppression is to normal biology. Mutations in the SCN9A gene, which encodes the Nav1.7 sodium channel critical for transmitting pain signals in peripheral nerves, can produce congenital insensitivity to pain. Two novel SCN9A mutations were identified in one case that resulted in partial, rather than complete, pain insensitivity, suggesting the mutations produced reduced rather than absent channel function.³¹ People with complete loss-of-function mutations in this gene feel no pain at all, which sounds enviable until you consider the consequences: undetected fractures, burns, infections, and joint destruction from injuries that go unnoticed. Pain suppression systems evolved not to eliminate pain but to regulate it, a distinction that matters enormously.

From an evolutionary perspective, the body’s pain modulation systems exist to balance two competing needs: the need to detect tissue damage and the need to function despite it. Sensitization after injury, which lowers the threshold for feeling pain in the affected area, is adaptive because it encourages protection of injured tissue. But this same sensitization system is vulnerable to runaway feedback, where lowering the threshold makes further activation more likely, creating a cycle. Additional regulatory systems appear to have evolved specifically to protect against this kind of escalation, and failures in those protective systems may underlie some chronic pain syndromes.³²